Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2012

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2012', provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) therapeutic pipeline. This report provides information on the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD). 'Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Non Alcoholic Fatty Liver Disease (NAFLD).
- A review of the Non Alcoholic Fatty Liver Disease (NAFLD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) pipeline depth and focus of Non Alcoholic Fatty Liver Disease (NAFLD) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutic Products under Development, Key Players in Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Overview, Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline, Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Assessment SHOW LESS READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Non Alcoholic Fatty Liver Disease (NAFLD) Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Non Alcoholic Fatty Liver Disease (NAFLD) 7
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics under Development by Companies 9
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics under Investigation by Universities/Institutes 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics – Products under Development by Companies 15
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Development 17
F. Hoffmann-La Roche Ltd. 17
Glenmark Pharmaceuticals Ltd. 18
Phynova Group Ltd 19
Antipodean Pharmaceuticals, Inc. 20
7TM Pharma A/S 21
Galmed International Ltd. 22
Connexios Life Sciences Pvt. Ltd. 23
Non Alcoholic Fatty Liver Disease (NAFLD) – Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
TM38837 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
PYN-22 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
MitoQ - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Aramchol - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
RO5093151 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
GRC 9332 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Berberine - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
CNX-FC010 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Tranilast - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics – Drug Profile Updates 40
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics – Discontinued Products 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 44
Disclaimer 44

List of Tables
Number of Products Under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H2 2012 7
Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD) – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
F. Hoffmann-La Roche Ltd., H2 2012 17
Glenmark Pharmaceuticals Ltd., H2 2012 18
Phynova Group Ltd, H2 2012 19
Antipodean Pharmaceuticals, Inc., H2 2012 20
7TM Pharma A/S, H2 2012 21
Galmed International Ltd., H2 2012 22
Connexios Life Sciences Pvt. Ltd., H2 2012 23
Assessment by Monotherapy Products, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 28
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics – Drug Profile Updates 40
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics – Discontinued Products 42

List of Figures
Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H2 2012 7
Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD) – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 24
Assessment by Route of Administration, H2 2012 25
Assessment by Stage and Route of Administration, H2 2012 26
Assessment by Molecule Type, H2 2012 27
Assessment by Stage and Molecule Type, H2 2012 28